JP4653314B2 - Ｐｄｅ−ｉｖ阻害作用を有するフェニルフェナントリジン - Google Patents

Ｐｄｅ−ｉｖ阻害作用を有するフェニルフェナントリジン Download PDF

Info

Publication number
JP4653314B2
JP4653314B2 JP2000593588A JP2000593588A JP4653314B2 JP 4653314 B2 JP4653314 B2 JP 4653314B2 JP 2000593588 A JP2000593588 A JP 2000593588A JP 2000593588 A JP2000593588 A JP 2000593588A JP 4653314 B2 JP4653314 B2 JP 4653314B2
Authority
JP
Japan
Prior art keywords
alkyl
hydrogen
alkoxy
phenyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000593588A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002534508A5 (enExample
JP2002534508A (ja
Inventor
フロッケルツィ ディーター
アムシュラー ヘルマン
グルントラー ゲアハルト
ハッツェルマン アルミン
ブントシュー ダニエラ
ボイメ ロルフ
ボス ヒルデガルト
クライ ハンス−ペーター
グッテラー ベアーテ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda GmbH
Original Assignee
Nycomed GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed GmbH filed Critical Nycomed GmbH
Publication of JP2002534508A publication Critical patent/JP2002534508A/ja
Publication of JP2002534508A5 publication Critical patent/JP2002534508A5/ja
Application granted granted Critical
Publication of JP4653314B2 publication Critical patent/JP4653314B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/10—Aza-phenanthrenes
    • C07D221/12—Phenanthridines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
JP2000593588A 1999-01-15 2000-01-12 Ｐｄｅ−ｉｖ阻害作用を有するフェニルフェナントリジン Expired - Fee Related JP4653314B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99100694 1999-01-15
EP99100694.1 1999-01-15
PCT/EP2000/000172 WO2000042020A1 (en) 1999-01-15 2000-01-12 Phenylphenanthridines with pde-iv inhibiting activity

Publications (3)

Publication Number Publication Date
JP2002534508A JP2002534508A (ja) 2002-10-15
JP2002534508A5 JP2002534508A5 (enExample) 2007-03-01
JP4653314B2 true JP4653314B2 (ja) 2011-03-16

Family

ID=8237351

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000593588A Expired - Fee Related JP4653314B2 (ja) 1999-01-15 2000-01-12 Ｐｄｅ−ｉｖ阻害作用を有するフェニルフェナントリジン

Country Status (32)

Country Link
US (1) US6476025B1 (enExample)
EP (2) EP1147089B1 (enExample)
JP (1) JP4653314B2 (enExample)
KR (1) KR100720906B1 (enExample)
CN (1) CN1152864C (enExample)
AT (1) ATE312081T1 (enExample)
AU (1) AU774868B2 (enExample)
BG (1) BG65126B1 (enExample)
BR (1) BR0007527B1 (enExample)
CA (1) CA2359440C (enExample)
CY (1) CY1106436T1 (enExample)
CZ (1) CZ300366B6 (enExample)
DE (1) DE60024581T2 (enExample)
DK (1) DK1147089T3 (enExample)
EA (1) EA003780B1 (enExample)
EE (1) EE05105B1 (enExample)
ES (1) ES2254132T3 (enExample)
HK (1) HK1040997B (enExample)
HR (1) HRP20010578A2 (enExample)
HU (1) HU227624B1 (enExample)
ID (1) ID29070A (enExample)
IL (2) IL144026A0 (enExample)
NO (1) NO320182B1 (enExample)
NZ (1) NZ512872A (enExample)
PL (1) PL205670B1 (enExample)
RS (1) RS50297B (enExample)
SI (1) SI1147089T1 (enExample)
SK (1) SK286946B6 (enExample)
TR (2) TR200501553T2 (enExample)
UA (1) UA69436C2 (enExample)
WO (1) WO2000042020A1 (enExample)
ZA (1) ZA200104864B (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001267589A1 (en) * 2000-07-14 2002-01-30 Byk Gulden Lomberg Chemische Fabrik G.M.B.H. Cycloalkyl - or cycloalkylmethyl-substituted 6-phenylphenanthridines
CA2495597A1 (en) * 2002-08-17 2004-03-04 Altana Pharma Ag Novel phenanthridines
CA2496459C (en) * 2002-08-29 2013-06-25 Altana Pharma Ag 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors
AU2003255493B8 (en) 2002-08-29 2009-03-26 Takeda Gmbh 2-hydroxy-6-phenylphenanthridines as PDE-4 inhibitors
US6894061B2 (en) 2002-12-04 2005-05-17 Wyeth Substituted dihydrophenanthridinesulfonamides
JP2007500686A (ja) * 2003-07-31 2007-01-18 アルタナ　ファルマ　アクチエンゲゼルシャフト 新規の６−フェニルフェナントリジン
EP1658270A1 (en) * 2003-07-31 2006-05-24 ALTANA Pharma AG Novel 6-phenylphenantridines
WO2005023253A1 (en) * 2003-09-05 2005-03-17 Altana Pharma Ag Use of pde4 inhibitors for the treatment of diabetes mellitus
EP1720835B1 (en) * 2004-02-18 2012-12-12 Nycomed GmbH Novel guanidinyl-substituted hydroxy-6-phenylphenanthridines as effective phosphodiesterase (pde) 4 inhibitors
AR049419A1 (es) * 2004-03-03 2006-08-02 Altana Pharma Ag Hidroxi-6-fenilfenantridinas sustituidas con heterociclilo
PL2589599T4 (pl) 2004-03-03 2015-06-30 Takeda Gmbh Nowe hydroksy-6-heteroarylofenantrydyny i ich zastosowanie jako inhibitorów PDE4
AU2005220034A1 (en) * 2004-03-09 2005-09-15 Nycomed Gmbh Novel isoamido-substituted hydroxy-6-phenylphenanthridines and their use as PDE4 inhibitors
MXPA06009892A (es) * 2004-03-10 2007-03-01 Altana Pharma Ag Nuevas hidroxi-6-fenilfenantridinas sustituidas con amido y su uso como inhibidores de la fosfodiesterasa tipo 4 (pde4).
BRPI0508471A8 (pt) * 2004-03-10 2019-01-15 Altana Pharma Ag compostos de hidróxi-6-fenilfenantidinas substituídas por difluoroetóxi, composição farmacêutica e uso para a produção dos mesmos
CA2558390A1 (en) * 2004-03-10 2005-09-22 Altana Pharma Ag Novel thio-containing hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors
US7589205B2 (en) * 2004-09-08 2009-09-15 Nycomed Gmbh 3-thia-10-aza-phenanthrene derivatives
US7411093B2 (en) * 2004-12-20 2008-08-12 Hoffman-La Roche Inc. Aminocycloalkanes as DPP-IV inhibitors
ES2337083T3 (es) 2005-03-02 2010-04-20 Nycomed Gmbh (2r,4ar,10br)-6-(2,6-dimetoxipiridin-3-il)-9-exoti-8-metoxi-1,2,3,4,4a,10b-hexahidrofenantridin-2-ol, sal de hc1.
CN102600144A (zh) 2005-03-08 2012-07-25 奈科明有限责任公司 治疗糖尿病的罗氟司特
AU2006221957A1 (en) * 2005-03-09 2006-09-14 Nycomed Gmbh Amido-substituted 6-phenylphenanthridines
KR101178674B1 (ko) 2007-10-04 2012-08-30 에프. 호프만-라 로슈 아게 사이클로프로필 아릴 아마이드 유도체 및 이의 용도
EP2794565B1 (en) 2011-12-21 2017-07-26 Novira Therapeutics Inc. Hepatitis b antiviral agents
CA2881057C (en) 2012-08-28 2020-10-27 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
JP6466348B2 (ja) 2013-02-28 2019-02-06 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー スルファモイル−アリールアミドおよびｂ型肝炎を処置するための医薬品としてのその使用
HUE033542T2 (en) 2013-04-03 2017-12-28 Janssen Sciences Ireland Uc Their use as medicaments for the treatment of N-phenylcarboxamide derivatives and hepatitis B
HUE040446T2 (hu) 2013-05-17 2019-03-28 Janssen Sciences Ireland Uc Szulfamoiltiofenamid-származékok és gyógyszerként történõ alkalmazásuk hepatitis B kezelésére
TW202126620A (zh) 2013-05-17 2021-07-16 愛爾蘭商健生科學愛爾蘭無限公司 胺磺醯基吡咯醯胺衍生物及其作為用於治療ｂ型肝炎藥物的用途
WO2015011281A1 (en) 2013-07-25 2015-01-29 Janssen R&D Ireland Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
MX368158B (es) 2013-10-23 2019-09-20 Janssen Sciences Ireland Uc Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
JP6553059B2 (ja) 2014-02-05 2019-07-31 ノヴィラ・セラピューティクス・インコーポレイテッド Ｈｂｖ感染の治療のための併用療法
PL3102572T3 (pl) 2014-02-06 2019-04-30 Janssen Sciences Ireland Uc Pochodne sulfamoilopirolamidu i ich zastosowanie jako leki do leczenia wirusowego zapalenia wątroby typu B
EP3271019A1 (en) 2015-03-19 2018-01-24 Novira Therapeutics Inc. Azocane and azonane derivatives and methods of treating hepatitis b infections
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
AR106192A1 (es) 2015-09-29 2017-12-20 Novira Therapeutics Inc Formas cristalinas de un agente antiviral contra la hepatitis b
WO2017181141A2 (en) 2016-04-15 2017-10-19 Novira Therapeutics, Inc. Combinations and methods comprising a capsid assembly inhibitor
SG11202007097QA (en) 2018-03-14 2020-08-28 Janssen Sciences Ireland Unlimited Co Capsid assembly modulator dosing regimen
AU2020223865A1 (en) 2019-02-22 2021-07-15 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
BR112021021454A2 (pt) 2019-05-06 2021-12-21 Janssen Sciences Ireland Unlimited Co Derivados de amida úteis no tratamento da infecção por hbv ou doenças induzidas por hbv

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3899494A (en) 1970-05-13 1975-08-12 Sandoz Ltd Substituted 6-phenyl benzo-naphthyridines
EE03523B1 (et) * 1996-01-31 2001-10-15 Byk Gulden Lomberg Chemische Fabrik Gmbh Fenantridiinid, neid sisaldavad ravimid ja nende kasutamine
US6127378A (en) 1996-03-26 2000-10-03 Byk Gulden Lomberg Chemische Fabrik Gmbh Phenanthridines substituted in the 6 position
CA2250569C (en) * 1996-03-26 2005-05-10 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel phenanthridines substituted in the 6 position
DK0937074T3 (da) * 1996-11-11 2003-06-23 Altana Pharma Ag Benzonaphthyridiner som bronkiale terapeutiske midler
SI0968211T1 (en) 1997-03-07 2004-02-29 Altana Pharma Ag Tetrazole derivatives
AU8106598A (en) 1997-06-03 1998-12-21 Byk Gulden Lomberg Chemische Fabrik Gmbh Benzonaphthyridine
PT1000035E (pt) 1997-07-25 2003-04-30 Altana Pharma Ag 6-fenilfenantridinas substituidas
AU753615B2 (en) * 1997-07-25 2002-10-24 Altana Pharma Ag Novel tetrazole derivatives
EP1147103B1 (en) * 1999-01-15 2005-05-04 ALTANA Pharma AG Phenantrhridine-n-oxides with pde-iv inhibiting activity
DE60025327T2 (de) * 1999-01-15 2006-08-24 Altana Pharma Ag 6-arylphenanthridine mit pde-iv hemmender wirkung
AU2107700A (en) * 1999-01-15 2000-08-01 Byk Gulden Lomberg Chemische Fabrik Gmbh Phenanthridine-n-oxides with pde-iv inhibiting activity

Also Published As

Publication number Publication date
EP1147089A1 (en) 2001-10-24
KR100720906B1 (ko) 2007-05-25
US6476025B1 (en) 2002-11-05
EP1147089B1 (en) 2005-12-07
NZ512872A (en) 2003-07-25
CY1106436T1 (el) 2011-10-12
ES2254132T3 (es) 2006-06-16
SK9802001A3 (en) 2001-12-03
EA003780B1 (ru) 2003-08-28
IL144026A (en) 2007-05-15
HRP20010578A2 (en) 2002-08-31
HU227624B1 (en) 2011-09-28
EE200100350A (et) 2002-10-15
NO20013341D0 (no) 2001-07-05
AU2289600A (en) 2000-08-01
CN1336919A (zh) 2002-02-20
NO20013341L (no) 2001-09-17
DE60024581D1 (de) 2006-01-12
EE05105B1 (et) 2008-12-15
DK1147089T3 (da) 2006-04-10
RS50297B (sr) 2009-09-08
TR200501553T2 (tr) 2005-06-21
WO2000042020A1 (en) 2000-07-20
HUP0105001A3 (en) 2002-10-28
DE60024581T2 (de) 2006-08-10
BG65126B1 (bg) 2007-03-30
SI1147089T1 (sl) 2006-04-30
HK1040997A1 (en) 2002-06-28
CZ300366B6 (cs) 2009-05-06
BR0007527B1 (pt) 2011-12-27
CA2359440A1 (en) 2000-07-20
PL205670B1 (pl) 2010-05-31
SK286946B6 (sk) 2009-08-06
EP1650193A2 (en) 2006-04-26
ID29070A (id) 2001-07-26
CZ20012248A3 (cs) 2001-09-12
YU48701A (sh) 2004-05-12
ATE312081T1 (de) 2005-12-15
IL144026A0 (en) 2002-04-21
EA200100731A1 (ru) 2002-02-28
BG105561A (en) 2001-12-29
AU774868B2 (en) 2004-07-08
ZA200104864B (en) 2003-04-15
HK1040997B (en) 2006-07-14
TR200101938T2 (tr) 2001-12-21
CN1152864C (zh) 2004-06-09
CA2359440C (en) 2009-04-14
KR20010086164A (ko) 2001-09-08
BR0007527A (pt) 2001-12-04
HUP0105001A2 (hu) 2002-04-29
UA69436C2 (uk) 2004-09-15
PL348925A1 (en) 2002-06-17
NO320182B1 (no) 2005-11-07
JP2002534508A (ja) 2002-10-15
EP1650193A3 (en) 2006-10-04

Similar Documents

Publication Publication Date Title
US6476025B1 (en) Phenylphennanthridines with PDE-IV inhibiting activity
JP4138003B2 (ja) 新規のフェナントリジン
US6410551B1 (en) Tetrazole derivatives
JP2005537312A (ja) 新規のフェナントリジン
HUP0003311A2 (en) Substituted 6-phenylphenanthridine derivatives, pocess for producing them and pharmaceutical compositions containing them
US6534518B1 (en) Polysubstituted 6-phenylphenanthridines with PDE-IV inhibiting activity
US6534519B1 (en) Phenanthridine-N-oxides with PDE-IV inhibiting activity
CZ20002218A3 (cs) Dihydrobenzofuranové deriváty
US6214839B1 (en) Substituted 6-alkylphenanthridines
JP2002534507A (ja) 新規６−アリールフェナントリジン
JP2002534505A (ja) 新規フェナントリジン−ｎ−オキシド
AU782908B2 (en) Phenanthridine-N-oxides
US20060189641A1 (en) Novel 6-phenlyphenanthridines
MXPA01007146A (en) Phenylphenanthridines with pde-iv inhibiting activity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100603

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20100610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100803

RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7433

Effective date: 20100827

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100830

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101102

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20101203

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20101217

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131224

Year of fee payment: 3

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131224

Year of fee payment: 3

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

LAPS Cancellation because of no payment of annual fees